In Vitro And In Vivo Evaluation Release of Nanosuspension Containing Antilipidemic Drugs

Abstract

quotHyperlipidemiaquot refers to a group of inherited and acquired illnesses that are characterized by high lipid levels in the body. It has been established that high cholesterol and LDL in the blood are the primary causes of atherosclerotic arteries, while high concentrations of HDL in the blood are beneficial. Many drug are available to lower the lipid level but they are associated with lots of side effects like myopathy, rhabdomyolysis, myalgia and arthralgia to overcome this problem selection of herbal drug is main approach for this study. Drugs that are poorly soluble in both aqueous and lipid media can have their solubility increased by the use of nanosuspension. By creating a nanosuspension, the research intends to boost the bioavailability of blueberries. Blueberry contains anthocyanins which show antihyperlipidemic activity, but the main problem associated with its low bioavailability which is the main hindrances in its therapeutic action for hyperlipidemia. As a result, blueberry nanosuspension was prepared and examined for various parameters in order to improve its bioavailability. Box Behnken design was applied to predict the effect of independent variables namely concentration of chitosan and concentration of tripolyphosphate (TPP) and stirring speed on two responses namely particle size and entrapment efficiency. The design suggested that a formulation having a particle size of 205.05nm and entrapment efficiency of 76.60 % will be an optimized formulation if it has chitosan, TPP, and stirring speed of 0.5%, 0.05%, and 1050 rpm respectively. The formulation suggested by Box Behnken design was prepared and it was found that particle size and entrapment efficiency of nanosuspension 198.5 nm and 75.14±0.56 % respectively. In addition, it was found to have polydispersity index, refractive index and zeta potential of 0.351, 1.33, 21.08 mv respectively. SEM analysis showed the droplet size under 200nm. newline